


Reduced *Trichomonas vaginalis* viability in mice pretreated with parasite DNA

Marco Antonio Barajas-Mendiola¹, Laura E. Castellano², Miriam Barrios-Rodiles³, Martha A. Deveze-Alvarez⁴, Eva E. Avila¹ and Patricia Cuéllar-Mata¹ 

Research Article

Cite this article: Barajas-Mendiola MA, Castellano LE, Barrios-Rodiles M, Deveze-Alvarez MA, Avila EE, Cuéllar-Mata P (2019). Reduced *Trichomonas vaginalis* viability in mice pretreated with parasite DNA. *Parasitology* **146**, 1636–1645. <https://doi.org/10.1017/S0031182019001094>

Received: 25 January 2019
Revised: 5 July 2019
Accepted: 29 July 2019
First published online: 28 August 2019

Key words:

Macrophage polarization; parasite DNA; parasite viability; *Trichomonas vaginalis*

Author for correspondence:

Patricia Cuéllar-Mata,
E-mail: mata@ugto.mx

¹Departamento de Biología, Universidad de Guanajuato, Guanajuato, Mexico; ²Departamento de Ingenierías Química, Electrónica y Biomédica, Universidad de Guanajuato, Guanajuato, Mexico; ³Center for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada and ⁴Departamento de Farmacia, Universidad de Guanajuato, Guanajuato, Mexico

Abstract

Trichomonas vaginalis is an extracellular parasite that colonizes the human urogenital tract leading to trichomoniasis, the most common sexually-transmitted non-viral disease worldwide. The immune response plays a critical role in the host defense against this parasite. *Trichomonas* DNA contains unmethylated CpG motifs (CpGDNA) that in other microorganisms act as modulators of the immune response. However, the molecular mechanisms responsible for CpGDNA immune modulation are still unclear. As macrophages participate in the first line of defense against infection, we investigated the type of immune response of murine macrophages to *T. vaginalis* DNA (*Tv*DNA). We observed high expression of the proinflammatory cytokines IL-6 and IL-12p40 in macrophages stimulated with *Tv*DNA. In contrast, the anti-inflammatory response, assessed by IL-10 and IL-13 mRNA expression was delayed. This suggests that the immune response induced by *Tv*DNA is modulated through cytokine production, mediated partly by NADPH-oxidase activity, as *Tv*DNA induced reactive species of oxygen production and a rounded morphology in macrophages indicative of an M1 phenotype. Furthermore, infected mice pretreated with *Tv*DNA displayed persistent vulvar inflammation and decreased parasite viability consistent with higher proinflammatory cytokine levels during infection compared to untreated mice. Overall, our findings suggest that *Tv*DNA pretreatment modulates the immune response favouring parasite elimination.

Introduction

Trichomonas vaginalis is a flagellated parasite that infects the genito-urinary tract of humans. It is the causal agent of trichomoniasis, one of the most common non-viral sexually transmitted diseases worldwide with an estimated 276 million cases per year according to the World Health Organization (WHO) (Newman *et al.*, 2015). Currently, trichomoniasis is associated with a high risk of acquiring human immunodeficiency virus (HIV) and human papillomavirus (HPV) (Lazenby *et al.*, 2014; Ghosh *et al.*, 2017), and may lead to adverse pregnancy outcomes (Silver *et al.*, 2014; Mielczarek and Blaszkowska, 2016). Furthermore, resistance to 5-nitroimidazoles, the conventional clinical treatment for this infection, has been observed in some *T. vaginalis* strains (Dunne *et al.*, 2003), making difficult their use in symptomatic patients.

Trichomonas vaginalis adheres to epithelial cells and survives in the urogenital tract of the host (da Costa *et al.*, 2005; Pereira-Neves and Benchimol, 2007), hence the mucosal immune response is the first line of defense against this pathogen. Particularly, the innate immune system plays a critical role in the containment and elimination of the parasites through the action of specialized cells including neutrophils, dendritic cells and macrophages (Iwasaki and Medzhitov, 2015; Sica *et al.*, 2015). Apart from their phagocytic function, macrophages' plasticity allows them to acquire different phenotypes with distinct biological functions depending on the microenvironment or metabolic state of the host (Martinez and Gordon, 2014; Fraternali *et al.*, 2015; Tan *et al.*, 2016; Murray, 2017). For example, macrophages activated by either a TLR agonist as LPS or microbial products, M(LPS + IFN γ), display an M1 phenotype, critical for elimination of pathogens. Macrophages activated by IL-4, M(IL-4), show an M2 phenotype to promote wound healing and inflammation resolution (Martinez and Gordon, 2014; Murray *et al.*, 2014).

Macrophages recognize Pathogen-Associated Molecular Patterns (PAMP's) through Receptor Recognition Patterns (RRPs) (Takeuchi and Akira, 2010; Broz and Monack, 2013). Upon activation of RRP's, a complex signalling pathway is triggered that culminates with the activation of transcription factors inducing the expression of inflammatory genes (Takeuchi and Akira, 2010; Kumar *et al.*, 2011; Broz and Monack, 2013), reactive oxygen species (ROS) like superoxide anion, and nitric oxide (NO) production (Forman and Torres, 2002; Bogdan, 2015), all of which will contribute to pathogen elimination. Toll-like receptor 9 (TLR9) is one member of the TLRs family expressed predominantly in dendritic cells, B lymphocytes and macrophages, and is localized in the endoplasmic reticulum, endosomes and lysosomes (Hemmi *et al.*, 2000; Latz *et al.*, 2004; Farrokhi *et al.*, 2017). TLR9 recognizes unmethylated CpG dinucleotides (CpG DNA), which are common in bacterial, viral and protozoan genomes (Shoda *et al.*, 2001;

Ahmad-Nejad *et al.*, 2002; Krieg, 2002) but are rarely found (~1%) in mammalian genomes (Jones and Takai, 2001; Krieg, 2002). Several reports have demonstrated that CpG DNA has immunostimulatory properties, inducing both maturation and activation of professional phagocytes as well as promoting a Th1 immune response (Messina *et al.*, 1991; Stacey *et al.*, 1996; Krieg, 2000, 2002), all of which is important to resolve infections. It has also been shown, both *in vitro* and *in vivo*, that parasite CpG DNA displays immunostimulatory effects on diverse immune cells *via* TLR activation and pro-inflammatory factor production, leading to improved infection resolution (Zimmermann *et al.*, 1998; Shoda *et al.*, 2001; Das *et al.*, 2015; Gong *et al.*, 2016). Furthermore, CpG DNA induces an enhanced mucosal immunity, which has resulted in its safe use in vaccines for humans as co-adjuvant (McGhee *et al.*, 1992; Stacey and Blackwell, 1999; Holmgren and Czerkinsky, 2005; Iho *et al.*, 2015). For example, the licensed Hepatitis B vaccine Engerix-B® (Halperin *et al.*, 2003) and the licensed Anthrax vaccine Bio Thrax® (Rynkiewicz *et al.*, 2011) both contain CpG ODN as an adjuvant. In this study, we hypothesized that *T. vaginalis* DNA (*TvDNA*) can have immunomodulatory functions. To address this, we evaluated the effect of *TvDNA* on the immune response *in vitro* (using RAW264.7 cells), in addition to an *in vivo* trichomoniasis murine model. Our data show that *TvDNA* elicits an increase of pro-inflammatory cytokines and induces a local inflammatory response. Furthermore, *TvDNA* is able to modulate the immune response favouring the host and contributing to parasite infection resolution.

Materials and methods

Cell lines and strains

RAW264.7 cells were maintained in DMEM GlutaMAX medium (10566-016, Gibco) supplemented with 10% foetal bovine serum (FBS) (16000-044, Gibco) at 37 °C in a 5% CO₂ atmosphere. *Trichomonas vaginalis* GT21 strain (Olmos-Ortiz *et al.*, 2017) was maintained in TYI-S-33 medium supplemented with 6% of adult bovine serum (ABS) (SU-120 microLab) and incubated at 37 °C.

Animals

Female BALB/c mice (6–8 weeks of age) were maintained under specifications from the Mexican Official Norm NOM-062-ZOO-1999 and fed *ad libitum*.

Trichomonas vaginalis DNA isolation

Parasites (3.8×10^6) were grown in 120 mL of TYS-33 medium supplemented with 6% of ABS at 37 °C for 24 h. The trophozoites were harvested by spinning down at 500×g for 5 min and the pellet was washed three times with phosphate solution buffer – Tris EDTA (PBS-EDTA) pH 7.2. *Trichomonas vaginalis* DNA (*TvDNA*) was isolated by two methods. In the first method, *TvDNA* was isolated using the Wizard Genomic DNA purification kit (A1120, Promega) with some modifications and additional phenol-chloroform isolation. In the second method, freshly isolated *TvDNA* using the Wizard Genomic DNA purification kit was additionally purified by affinity chromatography using the system DetoxiGel Endotoxin Removing Gel (20344, ThermoScientific) under the manufacturer's specification. Finally, *TvDNA* was quantified in a Gene-Quant spectrophotometer and stored at –20 °C until used.

Bacterial and mammalian DNA isolation

Escherichia coli DNA and mouse spleen DNA were isolated using the Wizard genomic DNA purification kit (Promega) following

the manufacturer's instructions. The bacterial and mammalian genomic DNA were quantified and stored as described above.

Limulus amoebocyte lysate-QCL and differential SDS-PAGE assay

To verify the purity of *TvDNA*, the endotoxin level from *TvDNA* was tested by limulus amoebocyte lysate (LAL)-QCL-1000 (5064-7U, LONZA) following the manufacturer's specifications. Additionally, 50 µg of *TvDNA* were analysed in SDS-PAGE and stained using three methods: Coomassie, silver and periodic acid-shift (PAS), to rule out any possible contamination of proteins and/or saccharides coming from the parasite. Moreover, 50 µg of *TvDNA* were used for electrophoresis on a 2% agarose gel and visualized under ethidium bromide staining to verify the integrity of *TvDNA*.

Nitric oxide production assay

The nitric oxide (NO) production in culture supernatants was indirectly determined by a modified Griess assay (Arias-Negrete *et al.*, 2004), evaluating the nitrite concentration released by RAW264.7 cells. Briefly, 2.5×10^5 macrophages were placed in 96-well plates and stimulated with *TvDNA* (50 µg mL⁻¹). Bacterial lipopolysaccharide (LPS, L3012 Sigma Aldrich) was used as a conventional positive control (Su *et al.*, 2011). Unstimulated macrophages and DNA from BALB/c mice spleen (50 µg mL⁻¹) were used as negative controls. To block LPS, cells were treated in the presence or absence of polymyxin B (25 mg mL⁻¹). The cells were incubated at 37 °C in a 5% CO₂ atmosphere for 36 h. The Griess assay was performed using 100 µL of macrophage supernatants, adding 50 µL of sulphanilamide solution and 50 µL of N-1-naphthyl-ethylenediamine. The reaction was performed at room temperature in the absence of light for 40 min. Nitrite accumulation was determined by spectrophotometry at 540 nm using a standard calibration curve of nitrite.

Semiquantitative RT-PCR

Expression of both pro-inflammatory cytokines (IL-6, IL-12p40, TNF) and anti-inflammatory cytokines (IL-10 and IL-13) in RAW264.7 cells was evaluated at different times of exposure to *TvDNA* (0.5, 1, 2, 3, 6, 9, 12, 15, 18 h). Briefly, total RNA was isolated from RAW264.7 cells incubated with *TvDNA* by TRIzol™ Reagent according to the manufacturer's instructions. Two micrograms of total RNA were treated with DNase I, amplification grade system to remove any trace of genomic DNA. Retrotranscriptase assays were performed using SuperScript™ III Reverse Transcriptase system according to the manufacturer's instructions. Expression level analysis for IL-6, IL-12p40, TNF, IL-10, IL-13 and GAPDH (as control), was performed by Platinum® PCR SuperMix using the specific oligonucleotides (Table S2). The amplification conditions for IL-6, TNF and GAPDH were: first denaturalization at 94 °C/3 min (1 cycle), second denaturation at 94 °C/30 s, followed by alignment at 51 °C/30 s and extension at 72 °C/1 min (35 cycles) and a final extension of 72 °C/10 min (1 cycle). The band sizes observed were 159 bp for IL-6, 203 bp for TNF and 300 bp for GAPDH. The amplification conditions for IL-10, IL-13 and IL-12p40 were: first denaturation at 94 °C/3 min (1 cycle), second denaturation at 94 °C/30 s, followed by alignment at 55 °C/30 s, extension at 72 °C/1 min (35 cycles) and a final extension at 72 °C/10 min (1 cycle). The observed band sizes were 563 bp for IL-10, 110 bp for IL-13 and 125 bp for IL-12p40. All amplification products were analysed in 2% agarose gels using ChemiDoc MP

Imaging Systems and the densitometric analysis was performed using software ImageLab4.0.

Macrophage polarization assay

Macrophages' morphological changes induced by *TvDNA* were determined by confocal microscopy. Briefly, 1×10^5 RAW264.7 macrophages were seeded on 12 mm coverslips placed inside the wells of 24-well tissue culture plates in DMEM without foetal bovine serum but containing the following stimuli: lipopolysaccharide (LPS) (10 ng mL^{-1}) plus interferon gamma ($\text{IFN-}\gamma$) (10 ng mL^{-1}) as positive control for M1 phenotype induction; IL-4 (20 ng mL^{-1}) as positive control for M2 phenotype induction and *TvDNA* ($50 \text{ }\mu\text{g mL}^{-1}$). Cells were incubated for 24 h with the different stimuli at 37°C in 5% CO_2 . Next, cells were washed three times with PBS. Macrophages were fixed with 2% paraformaldehyde and then washed twice with PBS-glycine. Finally, the cells were mounted with $10 \text{ }\mu\text{L}$ of ProLong™ Gold Antifade Mountant. Images were taken by confocal microscopy and were edited using ZEN 2 lite software. The morphology of 100 cells per field was evaluated. The axial ratio was calculated using ImageJ software (<https://imagej.nih.gov/ij/>) and reported as the aspect ratio.

Nitro blue tetrazolium assay

Reactive Oxygen Species (ROS) released from activated macrophages under different stimuli were determined by nitro blue tetrazolium (NBT) assay (Choi *et al.*, 2006). Macrophages (1×10^5 cells) were seeded into 96-well culture plates in DMEM without foetal bovine serum in the presence of lipopolysaccharide (LPS) (500 ng mL^{-1}) plus interferon gamma ($\text{IFN-}\gamma$) (10 ng mL^{-1}) as control for M1 phenotype induction, IL-4 (20 ng mL^{-1}) as control for M2 phenotype induction, *TvDNA* ($50 \text{ }\mu\text{g mL}^{-1}$) or diphenyleneiodonium (DPI) ($30 \text{ }\mu\text{M}$), a NADPH oxidase (Nox2) inhibitor. NBT (1 mg mL^{-1}) was added along with each different stimulus at the start of the assay to determine all released ROS. The plate was centrifuged at $800\times g$ for 1 min at room temperature and incubated at 37°C in a 5% CO_2 atmosphere for 40 min. Next, the supernatant was discarded and the cells were quickly washed with 70% methanol to remove any trace of non-reduced NBT. Formazan particles formed inside macrophages' phagosomes were solubilized with 2 mM KOH ($110 \text{ }\mu\text{L}$) and DMSO ($140 \text{ }\mu\text{L}$). Finally, released ROS was measured at 620 nm.

Trichomonas vaginalis infection in female BALB/c mice

Female BALB/c mice (6–8 weeks old) were used to establish *T. vaginalis* infection according to the protocol reported by Olmos-Ortiz *et al.* (2017). Five different groups, with five female BALB/c mice per group, were established. Four out of five groups were treated subcutaneously with $50 \text{ }\mu\text{L}$ of oestradiol valerate/norethisterone enanthate (MESIGYNA, BAYER) at 5 and 50 mg mL^{-1} , respectively (Fig. 4A). To explore the effect of *TvDNA*, two groups were treated with $50 \text{ }\mu\text{g mL}^{-1}$ of *TvDNA*, vaginally administered two days before infection. Two groups of mice were vaginally inoculated with 1×10^5 parasites in $50 \text{ }\mu\text{L}$ TYI-S-33 medium. From the second day until the tenth day post-infection, vaginal washes were collected. One group of five uninfected mice was used as a control. The *in vivo* experiments were conducted twice.

Vulvar inflammation evaluation

The parameters to define vulvar inflammation due to *T. vaginalis* infection, were vulvar irritation (redness), the presence of purulent secretions and vulvar size increase. The vulvar size increase

was evaluated by the length (in a number of pixels) of vulvar diameter over the rear width of each mouse on photos taken at each post-infection day. The vulvar size values were acquired in a double-blind fashion.

Trichomonas vaginalis viability in female BALB/c mice pretreated with *TvDNA*

To determine the effect of *TvDNA* pretreatment on the murine model of infection with live trophozoites, the parasites' viability at 4, 6 and 10 days post-infection was quantified using the LIVE/DEAD™ Viability/Cytotoxicity Kit system according to the manufacturer's instructions. Vaginal washes from female mice treated and untreated with *TvDNA* and later infected with the parasite were centrifuged at $400\times g$ for 10 min, the pellet was resuspended in $100 \text{ }\mu\text{L}$ of TYI-S-33 medium and deposited in culture tubes with 5 mL of TYI-S-33. The cultures were incubated at 37°C for 3 days. A culture tube with viable trophozoites from a regular culture and another with non-viable trophozoites (killed with methanol 70% at 37°C for 30 min) were incubated along with the culture tubes from the vaginal washes being tested. Next, the culture tubes were centrifuged at $500\times g$ for 5 min and the pellet was resuspended in $50 \text{ }\mu\text{L}$ of PBS to which $50 \text{ }\mu\text{L}$ of calcein $10 \text{ }\mu\text{M}$ (to distinguish live cells) and $100 \text{ }\mu\text{L}$ of ethidium homodimer $4 \text{ }\mu\text{M}$ (to identify dead cells) were added. The cell suspension was gently mixed and incubated for 30 min at room temperature in darkness. Afterwards, samples were centrifuged at $500\times g$ for 5 min, the pellet was washed twice with PBS and the trophozoites were fixed with 2% paraformaldehyde. Then, trophozoites were washed twice with PBS-glycine and resuspended in PBS. The trophozoites were mounted with $10 \text{ }\mu\text{L}$ of ProLong™ Gold Antifade Mountant. Images were taken by confocal microscopy and were edited using de software ZEN 2 lite. The ratio of calcein-AM (green-fluorescence) over ethidium-homodimer-1 (red fluorescence) parasite number was plotted as viability percentage.

Quantification of cytokines in vaginal washes of infected female mice

The effect of *TvDNA* on cytokine secretion was evaluated through changes in IL-6, IL-10 and IL-17 cytokine levels. These cytokines were quantified by ELISA kits (Invitrogen, San Diego, CA, USA: 88-7064-22 for IL-6, 88-7105-22 for IL-10 and eBiosciencie, Waltham, MA, USA: BMS6001 for IL-17) according to the manufacturer's guidelines. Cytokines were measured at 0, 4, 8, 10 and 14 days post-infection in mice pretreated with or without *TvDNA*. Mice treated with oestradiol valerate/norethisterone enanthate and untreated were used as control. We analysed the cytokine secretion in vaginal washes from *T. vaginalis*-infected mice from two independent experiments, collecting $150 \text{ }\mu\text{L}$ from each vaginal wash (in PBS at pH 7) at each day post-infection. Samples for each cytokine determination were performed using $50 \text{ }\mu\text{L}$ from the vaginal washes recovered. Data plotted correspond to the average from 10 mice per condition ($n = 10 \pm$ standard error).

Statistical analysis

The aspect ratio of the cells, nitrite and ROS production data were analysed by the Kruskal–Wallis test with subsequent Dun's test (three independent experiments). The parasite viability and the cytokine production *in vivo* experiments data were analysed by the Kruskal–Wallis test with subsequent Dun's test (two independent experiments). Vulvar inflammation data were analysed by the Kruskal–Wallis test and *post hoc* test. All data are presented as the mean \pm standard error.




Fig. 1. TvDNA induces NO production in RAW264.7 cells. NO production was determined in culture supernatants of untreated (black bars) and polymyxin B-treated (25 mg mL⁻¹, grey bars) RAW264.7 cells by the Griess modified assay after 36 h of incubation with LPS (10 ng mL⁻¹), mouse spleen DNA (50 µg mL⁻¹), *E. coli* DNA (50 µg mL⁻¹) or TvDNA (50 µg mL⁻¹). Degraded TvDNA was obtained after incubation with DNase I. Unstimulated macrophages were used as negative control. Data are representative of three independent experiments expressed as mean ± s.d. Significance was determined by Kruskal–Wallis analysis and Dunn's test ($n = 18$, *** $P < 0.001$). ns = non-significant.

Results

TvDNA induces NO production in RAW264.7 cells

Nitric oxide (NO) is a small inorganic radical that is implicated in the modulation of several physiological functions in mammals. In immune cells, NO is produced by inducible nitric oxide synthase (iNOS) and has beneficial microbicidal, antiparasitic, antiviral and antitumoral effects (Pautz *et al.*, 2010; Bogdan, 2015). External components of *T. vaginalis* activate human macrophages (Han *et al.*, 2009) as it has been reported that attenuated parasites induce NO production. Therefore, we tested whether TvDNA, an internal molecule of the parasite, could induce activation in RAW264.7 cells. Upon exposure to TvDNA (50 µg mL⁻¹) murine macrophages released nitrite at similar levels as bacterial LPS (10 ng mL⁻¹), the main component of the cell wall of Gram-negative bacteria (Fig. 1). In order to confirm that the activation was due to TvDNA and not to residual bacterial LPS contamination from the TvDNA isolation procedure, we added polymyxin B (which binds to LPS) (Galanos *et al.*, 1985; Schletter *et al.*, 1995; Raetz and Whitfield, 2002) to macrophages stimulated with TvDNA. The addition of polymyxin B did not abolish the NO production of macrophages stimulated with TvDNA as in those macrophages that were treated only with bacterial LPS or stimulated with *E. coli* DNA (Fig. 1). Importantly, there was no significant NO production by RAW264.7 cells stimulated with either DNase I-degraded TvDNA nor DNA obtained from mouse spleen (Fig. 1). Furthermore, the purity of TvDNA was assessed by endotoxin test (Table S1) and differential SDS-PAGE assays (Fig. S1A). Additionally, we evaluated the efficiency of two methods to obtain the parasite nucleic acid by determining the NO production in RAW264.7 cells treated with TvDNA (Fig. S1B). Our findings indicate that both 'isolated' and 'isolated and purified' TvDNA can activate macrophages for an efficient immune response starting with high NO production. Moreover, our data show that the integrity of TvDNA is required to induce macrophage activation (Fig. 1 and Fig. S1C). Henceforth, 'isolated' TvDNA was used in the following *in vitro* and *in vivo* experiments to further evaluate its effect.

TvDNA induces an early pro-inflammatory profile in murine macrophages

Our results indicated that TvDNA is a macrophage activator similar to bacterial LPS (Fig. 1). Next, we investigated the type of response induced by TvDNA through cytokine mRNA expression in RAW264.7 cells. Significant mRNA expression levels of IL-6, a pro-inflammatory cytokine, were induced within 30 min and a further increase on IL-6 mRNA was observed after up to 2 h of




Fig. 2. Early cytokine mRNA expression in RAW264.7 cells stimulated with TvDNA. Relative expression of IL-6 mRNA (A) and IL-10 mRNA (B) were evaluated by RT-PCR. GAPDH was used as a constitutive expression control. The densitometry analysis was performed in ImageLab6.0 software. Data are representative of three independent experiments expressed as the mean ± s.e. Significance was determined by Kruskal–Wallis analysis and Dunn's test ($n = 9$, * $P < 0.1$).

TvDNA treatment (Fig. 2A). In contrast, there was no significant increase in the anti-inflammatory cytokine IL-10 mRNA when RAW264.7 cells were stimulated with TvDNA for up to 2 h (Fig. 2B). We next looked at the effect of longer TvDNA exposure times on the mRNA levels of these cytokines. Interestingly, the highest IL-6 mRNA expression level was observed at 3 h followed by a gradual decrease after 18 h of TvDNA exposure (Fig. 3A). Although different in magnitude, a similar temporal effect was observed for the mRNA levels of pro-inflammatory cytokines TNF and IL-12p40 (Fig. 3B and C). The RAW264.7 macrophages required three hours to show a significant increase in IL-10 mRNA expression that reached the highest levels until 6 h of treatment. These increased IL-10 mRNA levels were sustained up to 15 h of TvDNA exposure and started to decrease by 18 h (Fig. 3D). On the other hand, the expression levels of IL-13,




Fig. 3. *TvDNA* induces an early proinflammatory and delayed anti-inflammatory profile in RAW264.7 cells. Relative expression of IL-6 (A), TNF (B), IL-12p40 (C), IL-10 (D) or IL-13 (E); mRNA levels were evaluated by RT-PCR. GAPDH was used as a control for a constitutively expressed gene. Data are representative of three independent experiments expressed as mean \pm s.e. Significance was determined by Kruskal–Wallis analysis and Dunn’s test ($n = 9$, * $P < 0.1$, *** $P < 0.05$, **** $P < 0.005$).

another anti-inflammatory cytokine, showed a significant increase 3 h after *TvDNA* treatment that was sustained throughout 18 h (Fig. 3E). Taken together, these findings suggest that *TvDNA* modulates macrophages’ response *via* a robust cytokine production through an early pro-inflammatory phase, followed by an anti-inflammatory profile to avoid an exacerbated inflammatory stage.

TvDNA induces NADPH oxidase (*Nox2*) activity and morphology changes in murine macrophages

Macrophages are professional phagocytes in which NO is a pro-inflammatory mediator that contributes to the elimination of pathogens (Bogdan, 2015). However, ROS production is also part of the microbicide machinery of these cells through NADPH oxidase activity (*Nox2*) (Warnatsch *et al.*, 2017). ROS, particularly superoxide anion, are involved in M1 and M2 macrophage differentiation (Martinez and Gordon, 2014; Murray, 2017). Thus, we first evaluated superoxide anion production using the nitro blue tetrazolium colorimetric assay (Choi *et al.*, 2006). Because ROS release occurs within minutes after stimulation (Choi *et al.*, 2006), we exposed RAW264.7 macrophages to *TvDNA* ($50 \mu\text{g mL}^{-1}$) for 40 min. As shown in Fig. 4A, macrophages displayed increased levels of ROS upon *TvDNA* treatment that were similar to those induced by a combination of LPS (500 ng mL^{-1}) plus IFN γ (10 ng mL^{-1}). Importantly, ROS production was inhibited when macrophages were treated with *TvDNA* plus DPI ($30 \mu\text{M}$), a selective inhibitor of *Nox2* (Kowluru and Kowluru, 2014; Zhu *et al.*, 2017). These results suggest that *TvDNA* promotes ROS production *via* *Nox2* activity. Interestingly, the inhibition of ROS levels with DPI was comparable to the low levels produced by macrophages that were treated with the anti-inflammatory cytokine IL-4, that promotes M2 phenotype in macrophages (Gordon, 2003; Martinez and Gordon, 2014). Because the role of M1 or M2 macrophages during *T. vaginalis* infection remains unknown, we next investigated whether *TvDNA* induced any morphological changes in RAW264.7 cells that characterize the functionally distinct M1/M2 phenotypes. Therefore, RAW264.7 macrophages were co-stimulated for 24 h with LPS (10 ng mL^{-1}) plus IFN γ (10 ng mL^{-1}). As expected, these macrophages displayed a ‘fried egg’-like shape, the characteristic morphology of M1 phenotype,

(Fig. 4B, bottom left). In contrast, macrophages stimulated with recombinant IL-4 (20 ng mL^{-1}) showed a fibroblast-like appearance, the characteristic morphology of M2 phenotype (Fig. 4B, top right). Strikingly, macrophages stimulated with *TvDNA* ($50 \mu\text{g mL}^{-1}$) largely displayed a ‘fried egg shape’ after 24 h of treatment (Fig. 4B, bottom right). The aspect ratio of macrophages reflecting the morphological changes induced by *TvDNA* and the other treatments was quantified and it is shown in Fig. 4C. These data indicate that the majority of *TvDNA*-treated cells displayed the M1 morphology profile, which prevailed over the M2 profile. Taken together, these findings show that *TvDNA* induces a burst of ROS release due to NADPH-oxidase activity, which may lead to a morphological and functional M1 phenotype in RAW264.7 macrophages. As previously shown (Sica *et al.*, 2015), this kind of macrophage activation can contribute to infection resolution.

TvDNA pretreatment promotes inflammation in female mice challenged with live parasites

The CpG motifs contained in the microbial genome have an immunomodulatory effect, and it has been shown that these sequences are able to counteract an infection using *in vivo* models (Shivhare *et al.*, 2014). Shivhare *et al.* (2014) observed in both hamster and murine models of visceral leishmaniasis an increase in mRNA expression for iNOS and pro-inflammatory cytokines when the infected animals had been pretreated with CpGODN enveloped in liposomes. On the other hand, IL-10 and TGF-beta mRNA levels decreased. This characteristic Th1 immune response was associated with a decrease in the parasitic burden for both infectious models.

Our results suggest that *TvDNA* modulates macrophages’ response through NO, cytokines and ROS production *in vitro*, presumably due to the CpG motifs contained in *T. vaginalis* genome. To determine how *TvDNA* impacts both infectivity and pathogenicity of this parasite, we investigated the *TvDNA* immunomodulatory effect in female BALB/c mice infected with *T. vaginalis*, using the *in vivo* infection model that we previously reported (Olmos-Ortiz *et al.*, 2017) (Fig. 5A). *TvDNA* was vaginally administered two days before infecting female mice with live trichomonas. Four days post-infection, both untreated and *TvDNA*-treated female mice, showed signs of trichomoniasis,




Fig. 4. ROS production and morphology changes induced by *TvDNA* in RAW264.7 cells. (A) ROS production in RAW264.7 was determined using the NBT assay after 40 min of treatment with different stimuli. Cells were incubated with LPS (500 ng mL⁻¹) plus IFN γ (10 ng mL⁻¹) or recombinant IL-4 (20 ng mL⁻¹) as M1 or M2 phenotype induction controls, respectively. Macrophages were incubated with *TvDNA* (50 μ g mL⁻¹) in the presence or absence of DPI (30 μ M), a Nox2 inhibitor. Unstimulated macrophages were used as a negative control. Data are representative of three independent experiments expressed as the mean \pm s.d. Significance was determined by Kruskal–Wallis analysis and Dunn’s test ($n=18$, $*P<0.025$). ns = non-significant. (B) Morphology changes were observed in RAW264.7 cells incubated for 24 h with LPS (10 ng mL⁻¹) plus IFN γ (10 ng mL⁻¹) as M1 phenotype control, while recombinant IL-4 (20 ng mL⁻¹) was used as M2 phenotype control. Macrophages were pretreated with *TvDNA* (50 μ g mL⁻¹) to determine its effect or left untreated to use as a negative control. Images were taken by confocal microscopy, Scale bar 20 μ m. Data are representative of three independent experiments. (C) Quantitative analysis of the morphological changes in macrophages induced by *TvDNA*. The aspect ratio for cells under different stimuli was measured and calculated using ImageJ software. Significance was determined by Kruskal–Wallis analysis and Dunn’s test ($***P<0.005$). One hundred cells per condition were analysed. ns = non-significant.

characterized by soft vulvar swelling, oedema formation, and whitish discharges. The vulvar oedema persisted up to 10 days post-infection in both groups of trophozoite-inoculated female mice. However, the infection signs were less evident in the infected group pre-treated with *TvDNA* (Fig. 5B). In parallel, we also measured the extent of the vulvar oedema by quantifying the number of pixels of vulvar diameter over the rear width for each mouse, at each post-infection day. Comparing the two mice groups, untreated and pretreated with *TvDNA*, there was no significant difference in vulvar oedema throughout the infection period, up to 10 days post-infection (Fig. 5C). For vulvar oedema measurements, we considered as zero time of infection, the mice prior to being subjected to infection. These findings suggest that pre-treatment of *TvDNA* induces and maintains an inflammatory reaction in the host, which could be important for infection resolution.

TvDNA pretreatment of female mice affects the viability of *T. vaginalis* during parasite infection

It has been reported that the immune stimulation triggered by CpG DNA induces a strong Th1 response, which is necessary to decrease parasite burden and to resolve the infection in a murine model of leishmaniasis (Ehrlich *et al.*, 2017). Our data suggest that *TvDNA* pretreatment induces a sustained inflammatory response in infected female mice (Fig. 5B and C), thus we hypothesized that this sustained inflammatory response could affect parasite viability. To demonstrate our hypothesis, we evaluated the viability of *T. vaginalis* trophozoites in vaginal washes obtained from infected female mice that were pretreated or not with *TvDNA* using a fluorescence microscopy assay that discriminates live vs dead trophozoites. As shown in Fig. 6B, we observed an increasing number of nonviable parasites from 4 to 10 days post-infection in *TvDNA* pretreated mice compared to the *TvDNA* untreated and infected mice (Fig. 6A). Next, we

quantified the viability of *T. vaginalis* recovered from vaginal washes in untreated and *TvDNA* pretreated mice. *TvDNA* pretreatment significantly decreased the viability of *T. vaginalis* at four days post-infection, with the most pronounced decrease at ten days post-infection. In contrast, the viability of trophozoites in untreated mice was not changed throughout the 10 days of infection (Fig. 6C). These findings suggest that *TvDNA* modulates the host response to favour the parasite elimination.

TvDNA pretreatment induces a higher production of pro-inflammatory cytokine IL-6 during parasite infection in mice

As shown in Fig. 5 we observed a sustained vulvar inflammation in mice pretreated with *TvDNA* and later infected with live trophozoites. Furthermore, we observed that *T. vaginalis* viability was significantly decreased by *TvDNA* pretreatment (Fig. 6). Thus, we hypothesized that these *TvDNA*-mediated events may be caused by a pro-inflammatory environment. To test this hypothesis we quantified IL-6, IL-10 and IL-17 cytokines in vaginal washes from mice untreated and pretreated with *TvDNA* and later infected with live trophozoites (Fig. 7A). Results from these measurements revealed significantly higher IL-6 levels from 4 to 14 days post-infection in *TvDNA*-pretreated mice compared to untreated ones (Fig. 7B). In striking contrast, IL-10 levels fell to undetectable levels at 4 to 10 days post-infection and only slightly rising after 14 days in *TvDNA*-pretreated mice (Fig. 7C). Interestingly, *TvDNA*-pretreated mice displayed significantly higher IL-17 cytokine production throughout the 14 days of infection compared to untreated but infected mice (Fig. 7D). Increased IL-17 levels are likely responsible for maintaining the inflammatory process in this condition. Taken together, these data indicate that *TvDNA* pretreatment promotes a pro-inflammatory environment that may contribute to decreasing the parasite viability to favour infection resolution.




Fig. 5. *TvDNA* promotes vulvar inflammation in infected mice. (A) Female mice were *TvDNA*-pretreated or not, then infected with live trophozoites and vaginal washes were collected at 0, 4, 6 and 10 days post-infection. (B) Development of vulvar oedema in untreated and *TvDNA*-pretreated ($50 \mu\text{g mL}^{-1}$) mice during ten days of infection with 5×10^6 trophozoites. Red arrows show the vulvar oedema and blue arrows show the persistence of vulvar oedema. (C) Evaluation of vulvar oedema at different days post-infection in untreated (black bars) and *TvDNA*-pretreated (grey bars) mice. Vulvar oedema at different days post-infection was calculated as the ratio of vulvar diameter (a = red line) over the mouse rear width (b = black line). Data are representative of two independent experiments expressed as the mean \pm s.d. Significance was determined by Kruskal–Wallis analysis and Dunn’s test ($n = 5$ per group, $P > 0.1$).




Fig. 6. Effect of *TvDNA* pretreatment on parasite viability in infected mice. (A) Vaginal washes from untreated and infected mice collected at 4, 6 and 10 days post-infection. Scale bar, $20 \mu\text{m}$. (B) Vaginal washes collected from infected mice pretreated with *TvDNA* at 4, 6 and 10 days post-infection. Scale bar $20 \mu\text{m}$. Live trophozoites are stained in green, while dead trophozoites are stained in red. (C) Viability rate of parasites in vaginal washes from untreated (black bars) and *TvDNA*-pretreated (grey bars) mice. Data are representative of two independent experiments expressed as the mean \pm s.d. Significance was determined by Kruskal–Wallis analysis and Dunn’s test ($n = 5$ per group, * $P < 0.1$, ** $P < 0.01$, *** $P < 0.001$).

Discussion

The mechanisms by which *T. vaginalis* establishes the infection and persist chronically in humans are still not completely elucidated. This is in spite of its ranking as first among STDs and

its alarming association with an elevated risk of cervical and prostate cancers (Shui *et al.*, 2016; Ghosh *et al.*, 2017). Trophozoites’ adhesion to host cells is one of the first steps whereby *T. vaginalis* initiates the infection. This action triggers a cascade of events




Fig. 7. Proinflammatory cytokine profile induced by *TvDNA* pretreatment on infected mice. (A) Female mice were *TvDNA*-pretreated or not, 2 days prior to being infected with live trophozoites. Vaginal washes were collected at 0, 4, 8, 10 and 14 days post-infection to quantify different cytokines. (B) IL-6, (C) IL-10 and (D) IL-17 levels in *TvDNA*-pretreated (grey bars) and untreated (black bars) mice infected with *Tv* were measured by ELISA at different days post-infection. Data were obtained from two independent experiments, with ten mice in total per evaluated condition. Graphs show the mean with standard error. Significance was determined by Kruskal-Wallis analysis and Dunn's test ($n = 5$ per group, $**P < 0.05$, $***P < 0.005$).

mediated by Pathogen-Associated Molecular Patterns (PAMPs) and the expression of compounds at the plasma membrane, including lipophosphoglycan (LPG) (Ryan *et al.*, 2011; Pasare, 2017) that contribute to the establishment of the parasite within the host. There is also a large body of evidence about PAMPs' ability to activate immune cells through nitric oxide, cytokine production and changes in the expression of some receptors on the surface of immune cells (Takeuchi and Akira, 2010; Kumar *et al.*, 2011; Broz and Monack, 2013).

Previous studies have demonstrated an important immunostimulatory effect of CpG DNA motifs from microbes and parasites that induce both the maturation and activation of professional phagocytes (Shoda *et al.*, 2001; Ahmad-Nejad *et al.*, 2002; Das *et al.*, 2015) as well as the promotion of a Th1 immune response (Krieg, 2000; Sabatel *et al.*, 2017) and T lymphocyte differentiation (Moseman *et al.*, 2004). Our study reveals *TvDNA* (a CpG DNA specific type) as a robust promoter of macrophages' proinflammatory profile (Figs 2, 3 and 4) that enables them to fight against the parasite (Fig. 6). That is, our data strongly suggest that *TvDNA* pretreatment can directly support the host in mounting an effective immune response. First, *TvDNA* induces a cytotoxic response by enhancing NO and ROS production in macrophages. Second, *TvDNA* promotes a substantial alteration on macrophages towards an M1 profile, inducing the expression of pro-inflammatory cytokines in addition to drastic morphological changes. Third, and most significant, *TvDNA* pretreatment has a prominent negative impact on parasite survival and an enhanced proinflammatory cytokine profile in our *in vivo* model of trichomoniasis. A potent adjuvant effect of CpG DNA has been previously reported on leishmaniasis, toxoplasmosis and trypanosomiasis (Zimmermann *et al.*, 2008; Rodríguez-Morales *et al.*, 2015; Gong *et al.*, 2016) showing an important protective Th1 immune response in parasitic disease (Chu *et al.*, 1997; Zimmermann *et al.*, 1998; Ramirez *et al.*, 2014). The transition of the immune response to a Th1 profile against a parasite like *T. vaginalis*, possibly induced

by polarization of macrophages to an M1 profile, led our interest on CpG DNA to understand the specific mechanisms of an immune response that would favour the host (Abou Fakhre *et al.*, 2009). Thus, our data suggest that *TvDNA* could exert an adjuvant effect on at least one type of immune cells, improving macrophage function during *T. vaginalis* infection. The early effect of *TvDNA* on macrophages could trigger a strong response potentially able to change the outcome of the host-parasite interaction. Apart from the general adjuvant effect of CpG DNA, it has been shown that specific sequences present in each pathogen genome could promote the specificity of the host immune response (Gupta *et al.*, 2015). Thus, there is a need to better understand the mechanisms regulating the response to CpG DNA from parasites such as trichomonas.

The transition of macrophages to M1 profile includes morphological changes that lead to the modulation of cytokines production by mechanisms still not well understood. McWhorter *et al.* (2015) have suggested that the lamellipodia formation could induce a new actin distribution pattern and showed that the macrophage plasticity is linked to its activation and function. It will be interesting to establish how cytoskeleton reorganization promotes macrophage polarization to achieve specific functional phenotypes and how these changes contribute to enhance the host response by decreasing trichomonas' viability.

In the present study, the lack of effect of *TvDNA* on vulvar oedema but the dramatic effect on trophozoite viability are opposite effects to those observed with *T. vaginalis* exosomal fractions (*TvELV*) in the pretreatment of infected mice which increased the IL-10 production, decreased the vulvar oedema and favoured the trophozoite viability in our murine infection model (Olmos-Ortiz *et al.*, 2017). Thus, it is possible that *TvDNA* induces macrophages to extend the proinflammatory response to prevent parasite population expansion in the host. The specific role of innate immune response in the host-parasite relationship during trichomoniasis is limited and requires further study.

Overall, our work suggests that *Tv*DNA is an immunomodulator that could redirect the result of the host–parasite interaction. Finally, *Tv*DNA could be considered as a potential adjuvant for vaccine development against trichomoniasis.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0031182019001094>.

Acknowledgements. We thank Felipe Padilla-Vaca, PhD and Fernando Anaya-Velázquez, PhD for donating *Tv* GT-21 strain. We also thank Mayra C. Rodriguez for technical support.

Financial support. We are grateful to CONACyT, Mexico for a scholarship provided to MABM and for financial support (Project No. 0182671 CB-2012-01). We thank the University of Guanajuato for financial support (Project No. 139 CIIC 2018, project No. 977 CIIC 2016-2017).

Conflict of interest. The authors declare that they have no conflict of interest.

Ethical standards. Permission for this study was granted by the Ethics Committee of the University of Guanajuato. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

References

- Abou Fakher FH, Rachinel N, Klimczak M, Louis J and Doyen N (2009) TLR9-dependent activation of dendritic cells by DNA from *Leishmania* major favors Th1 cell development and the resolution of lesions. *Journal of Immunology* **182**, 1386–1396.
- Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM and Wagner H (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. *European Journal of Immunology* **32**, 1958–1968.
- Arias-Negrete S, Jiménez-Romero LA, Solís-Martínez MO, Ramírez-Emiliano J, Avila EE and Cuéllar-Mata P (2004) Indirect determination of nitric oxide production by reduction of nitrate with a freeze-thawing-resistant nitrate reductase from *Escherichia coli* MC1061. *Analytical Biochemistry* **328**, 14–21.
- Bogdan C (2015) Nitric oxide synthase in innate and adaptive immunity: an update. *Trends in Immunology* **36**, 161–178.
- Broz P and Monack DM (2013) Newly described pattern recognition receptors team up against intracellular pathogens. *Nature Reviews Immunology* **13**, 551–565.
- Choi HS, Kim JW, Cha YN and Kim C (2006) A quantitative nitroblue tetrazolium assay for determining intracellular superoxide anion production in phagocytic cells. *Journal of Immunoassay & Immunochemistry* **27**, 31–44.
- Chu RS, Targoni OS, Krieg AM, Lehmann PV and Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *Journal of Experimental Medicine* **186**, 1623–1631.
- da Costa RF, de Souza W, Benchimol M, Alderete JF and Morgado-Díaz JA (2005) *Trichomonas vaginalis* perturbs the junctional complex in epithelial cells. *Cell Research* **15**, 704–716.
- Das S, Ghosh AK, Singh S, Saha B, Ganguly A and Das P (2015) Unmethylated CpG motifs in the *L. donovani* DNA regulate TLR9-dependent delay of programmed cell death in macrophages. *Journal of Leukocyte Biology* **97**, 363–378.
- Dunne RL, Dunn LA, Upcroft P, O'Donoghue PJ and Upcroft JA (2003) Drug resistance in the sexually transmitted protozoan *Trichomonas vaginalis*. *Cell Research* **13**, 239–249.
- Ehrlich AK, Fernández OL, Rodríguez-Pinto D, Castilho TM, Corral Caridad MJ, Goldsmith-Pestana K, Saravia NG and McMahon-Pratt D (2017) Local delivery of the toll-like receptor 9 ligand CpG downregulates host immune and inflammatory responses, ameliorating established *Leishmania* (Viannia) *panamensis* chronic infection. *Infection and Immunity* **85**, 1–6.
- Farrokhi S, Abbasirad N, Movahed A, Khazaei HA, Pishjoo M and Rezaei N (2017) TLR9-based immunotherapy for the treatment of allergic diseases. *Immunotherapy* **9**, 339–346.
- Forman HJ and Torres M (2002) Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. *American Journal of Respiratory and Critical Care Medicine* **166**, S4–S8.
- Fraternal A, Brundu S and Magnani M (2015) Polarization and repolarization of macrophages. *Journal of Clinical & Cellular Immunology* **6**, 2.
- Galanos C, Lüderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg M, Schade U, Imoto M and Yoshimura H (1985) Synthetic and natural *Escherichia coli* free lipid A express identical endotoxic activities. *European Journal of Biochemistry* **148**, 1–5.
- Ghosh I, Muwonge R, Mittal S, Banerjee D, Kundu P, Mandal R, Biswas J and Basu P (2017) Association between high risk human papillomavirus infection and co-infection with *Candida* spp. and *Trichomonas vaginalis* in women with cervical premalignant and malignant lesions. *Journal of Clinical Virology* **87**, 43–48.
- Gong P, Cao L, Guo Y, Dong H, Yuan S, Yao X, Ren W, Yao L, Xu Z, Sun Q and Zhang X (2016) Toxoplasma gondii: protective immunity induced by a DNA vaccine expressing GRA1 and MIC3 against toxoplasmosis in BALB/c mice. *Experimental Parasitology* **166**, 131–136.
- Gordon S (2003) Alternative activation of macrophages. *Nature Reviews Immunology* **3**, 23–35.
- Gupta CL, Akhtar S, Wayne A, Pandey NR, Pathak N and Bajpai P (2015) Cross talk between *Leishmania donovani* CpG DNA and Toll-like receptor 9: an immunoinformatics approach. *Biochemical and Biophysical Research Communications* **459**, 424–429.
- Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H and Eiden JJ (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. *Vaccine* **21**, 2461–2467.
- Han IH, Goo SY, Park SJ, Hwang SJ, Kim YS, Yang MS, Ahn MH and Ryu JS (2009) Proinflammatory cytokine and nitric oxide production by human macrophages stimulated with *Trichomonas vaginalis*. *Korean Journal of Parasitology* **47**, 205–212.
- Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S (2000) A Toll-like receptor recognizes bacterial DNA. *Nature* **408**, 740–745.
- Holmgren J and Czerkinsky C (2005) Mucosal immunity and vaccines. *Nature Medicine* **11**, S45–S53.
- Iho S, Maeyama J and Suzuki F (2015) CpG oligodeoxynucleotides as mucosal adjuvants. *Human Vaccines & Immunotherapeutics* **11**, 755–760.
- Iwasaki A and Medzhitov R (2015) Control of adaptive immunity by the innate immune system. *Nature Immunology* **16**, 343–353.
- Jones PA and Takai D (2001) The role of DNA methylation in mammalian epigenetics. *Science* **293**, 1068–1070.
- Kowluru A and Kowluru RA (2014) Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes. *Biochemical Pharmacology* **88**, 275–283.
- Krieg AM (2000) The role of CpG motifs in innate immunity. *Current Opinion in Immunology* **12**, 35–43.
- Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. *Annual Review of Immunology* **20**, 709–760.
- Kumar H, Kawai T and Akira S (2011) Pathogen recognition by the innate immune system. *International Reviews of Immunology* **30**, 16–34.
- Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. *Nature Immunology* **5**, 190–198.
- Lazenby GB, Unal ER, Andrews AL and Simpson K (2014) Cost-effectiveness analysis of annual *Trichomonas vaginalis* screening and treatment in HIV-positive women to prevent HIV transmission. *Sexually Transmitted Diseases* **41**, 353–358.
- Martínez FO and Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000prime Reports* **6**, 13.
- McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M and Kiyono H (1992) The mucosal immune system: from fundamental concepts to vaccine development. *Vaccine* **10**, 75–88.
- McWhorter FY, Davis CT and Liu WF (2015) Physical and mechanical regulation of macrophage phenotype and function. *Cellular and Molecular Life Sciences* **72**, 1303–1316.
- Messina JP, Gilkeson GS and Pisetsky DS (1991) Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. *Journal of Immunology* **147**, 1759–1764.
- Mielczarek E and Blaszkowska J (2016) *Trichomonas vaginalis*: pathogenicity and potential role in human reproductive failure. *Infection* **44**, 447–458.
- Moseman EA, Liang X, Dawson AJ, Panoskaltis-Mortari A, Krieg AM, Liu YJ, Blazar BR and Chen W (2004) Human plasmacytoid dendritic

- cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. *Journal of Immunology* **173**, 4433–4442.
- Murray PJ (2017) Macrophage polarization. *Annual Review of Physiology* **79**, 541–566.
- Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN and Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* **41**, 14–20.
- Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J and Temmerman M (2015) Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One* **10**, e0143304.
- Olmos-Ortiz LM, Barajas-Mendiola MA, Barrios-Rodiles M, Castellano LE, Arias-Negrete S, Avila EE and Cuéllar-Mata P (2017) *Trichomonas vaginalis* exosome-like vesicles modify the cytokine profile and reduce inflammation in parasite-infected mice. *Parasite Immunology* **39**(6).
- Pasare AJaC (2017) Innate control of adaptive immunity: beyond the three-signal paradigm. *Journal of Immunology* **198**, 3791–3800.
- Pautz A, Art J, Hahn S, Nowag S, Voss C and Kleinert H (2010) Regulation of the expression of inducible nitric oxide synthase. *Nitric Oxide* **23**, 75–93.
- Pereira-Neves A and Benchimol M (2007) Phagocytosis by *Trichomonas vaginalis*: new insights. *Biology of the Cell* **99**, 87–101.
- Raetz CR and Whitfield C (2002) Lipopolysaccharide endotoxins. *Annual Review of Biochemistry* **71**, 635–700.
- Ramirez L, Corvo L, Duarte MC, Chávez-Fumagalli MA, Valadares DG, Santos DM, de Oliveira CI, Escutia MR, Alonso C, Bonay P, Tavares CA, Coelho EA and Soto M (2014) Cross-protective effect of a combined L5 plus L3 *Leishmania* major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. *Parasites & Vectors* **7**, 3.
- Rodríguez-Morales O, Monteón-Padilla V, Carrillo-Sánchez SC, Rios-Castro M, Martínez-Cruz M, Carabarin-Lima A and Arce-Fonseca M (2015) Experimental vaccines against Chagas disease: a journey through history. *Journal of Immunology Research* **2015**, 489758.
- Ryan CM, de Miguel N and Johnson PJ (2011) *Trichomonas vaginalis*: current understanding of host–parasite interactions. *Essays in biochemistry* **51**, 161–175.
- Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS and Nielsen CJ (2011) Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. *Vaccine* **29**, 6313–6320.
- Sabatel C, Radermecker C, Fievez L, Paulissen G, Chakarov S, Fernandes C, Olivier S, Toussaint M, Pirottin D, Xiao X, Quatresooz P, Sirard JC, Cataldo D, Gillet L, Bouabe H, Desmet CJ, Ginhoux F, Marichal T and Bureau F (2017) Exposure to bacterial CpG DNA protects from airway allergic inflammation by expanding regulatory lung interstitial macrophages. *Immunity* **46**, 457–473.
- Schletter J, Heine H, Ulmer AJ and Rietschel ET (1995) Molecular mechanisms of endotoxin activity. *Archives of Microbiology* **164**, 383–389.
- Shivhare R, Vishwakarma P, Parmar N, Yadav PK, Haq W, Srivastava M, Gupta S and Kar S (2014) Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis. *PLoS One* **9**, e94596.
- Shoda LK, Kegerreis KA, Suarez CE, Roditi I, Corral RS, Bertot GM, Norimine J and Brown WC (2001) DNA from protozoan parasites *Babesia bovis*, *Trypanosoma cruzi*, and *T. brucei* is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor alpha, and nitric oxide. *Infection and Immunity* **69**, 2162–2171.
- Shui IM, Kolb S, Hanson C, Sutcliffe S, Rider JR and Stanford JL (2016) *Trichomonas vaginalis* infection and risk of advanced prostate cancer. *Prostate* **76**, 620–623.
- Sica A, Erreni M, Allavena P and Porta C (2015) Macrophage polarization in pathology. *Cellular and Molecular Life Sciences* **72**, 4111–4126.
- Silver BJ, Guy RJ, Kaldor JM, Jamil MS and Rumbold AR (2014) *Trichomonas vaginalis* as a cause of perinatal morbidity: a systematic review and meta-analysis. *Sexually Transmitted Diseases* **41**, 369–376.
- Stacey KJ and Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against *Leishmania* major. *Infection and Immunity* **67**, 3719–3726.
- Stacey KJ, Sweet MJ and Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. *Journal of Immunology* **157**, 2116–2122.
- Su YW, Chiou WF, Chao SH, Lee MH, Chen CC and Tsai YC (2011) Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF- κ B and AP-1 signaling pathways. *International Immunopharmacology* **11**, 1166–1172.
- Takeuchi O and Akira S (2010) Pattern recognition receptors and inflammation. *Cell* **140**, 805–820.
- Tan HY, Wang N, Li S, Hong M, Wang X and Feng Y (2016) The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. *Oxidative Medicine and Cellular Longevity* **2016**, 2795090.
- Warnatsch A, Tsurouktsoglou TD, Branzk N, Wang Q, Reincke S, Herbst S, Gutierrez M and Papayannopoulos V (2017) Reactive oxygen species localization programs inflammation to clear microbes of different size. *Immunity* **46**, 421–432.
- Zhu Y, Fan S, Wang N, Chen X, Yang Y, Lu Y, Chen Q, Zheng J and Liu X (2017) NADPH oxidase 2 inhibitor diphenyleneiodonium enhances ROS-independent bacterial phagocytosis in murine macrophages via activation of the calcium-mediated p38 MAPK signaling pathway. *American Journal of Translational Research* **9**, 3422–3432.
- Zimmermann S, Egeter O, Hausmann S, Lipford GB, Röcken M, Wagner H and Heeg K (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. *The Journal of Immunology* **160**, 3627–3630.
- Zimmermann S, Dalpke A and Heeg K (2008) CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. *International Journal of Medical Microbiology* **298**, 39–44.